<?xml version="1.0" encoding="UTF-8"?>
<p>Diagnosis of MERS by the WHO is defined initially as patients presenting with a fever, cough and hospitalization with suspicion of lower respiratory tract involvement.
 <xref rid="dyaa033-B12" ref-type="bibr">
  <sup>12</sup>
 </xref> Patient history was obtained upon hospitalization and prominent considerations for diagnosis involved a history of contact with probable or confirmed cases of the illness, or a reported history of travel or residence within the Arabian Peninsula. Severe cases were subjected to laboratory testing.
 <xref rid="dyaa033-B13" ref-type="bibr">
  <sup>13</sup>
 </xref> Similar to COVID-19, RT-PCR was used for diagnosis. Additional serum tests for antibodies of the virus were developed. In Saudi Arabia, a clinical trial revealed that a combination of lopinavirâ€“ritonavir and interferon beta-1b was shown to be effective among MERS cases.
 <xref rid="dyaa033-B14" ref-type="bibr">
  <sup>14</sup>
 </xref> Additionally, a broad-spectrum antiviral nucleotide prodrug named remdesivir presented potent efficacy for the treatment of MERS coronavirus and SARS coronavirus in preclinical studies.
 <xref rid="dyaa033-B15" ref-type="bibr">
  <sup>15</sup>
 </xref>
 <sup>,</sup>
 <xref rid="dyaa033-B16" ref-type="bibr">
  <sup>16</sup>
 </xref>
</p>
